CDD-162

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameCDD-162
Drug Alias NameTAK1 inhibitors (Confluence)TAK1 inhibitors (Confluence Life Sciences)intracellular pathways modulators (Confluence)CDD-162
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTGF-β activated kinase-1 inhibitors
TargetsTGF-β activated kinase-1
Therapy Area/IndicationsInflammationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesConfluence Life Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesConfluence Life Sciences IncAclaris Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsInflammationNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A